Cubist

Cubist will use Evotec's proprietary fragment screening technology, EVOlution^SM to complement discovery research efforts in two of its antibacterials programs. EVOlution^SM combines biochemical, nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) screening technologies for the screening of low molecular weight compounds and fragments.

In combination with fragment screening technology, Evotec will use its expertise in structural biology and protein crystallography in order to determine the 3-dimensional structure of the fragments bound to the targets of interest. To this end, Evotec will use its internal crystallography platform and will access the state-of-the-art synchrotron technology of the Diamond Light Source, its partner for protein crystallography. By providing this technology in combination with its fragment screening, Evotec will supply high quality results to Cubist to enable the structure-driven identification of drug candidates for their priority antibacterial targets.

25 Feb 2010
Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals

14 Jul 2009
Evotec announces Research Agreement on Fragment- Based Drug Discovery with Cubist Pharmaceuticals

Further Information

Integrated Services.pdf
(pdf - 56,68 kB)

Assay Development & Screening.pdf
(pdf - 520,11 kB)

Fragment-based Drug Discovery.pdf
(pdf - 876,2 kB)

Medicinal Chemistry and Early Develop...
(pdf - 90,85 kB)

ADMET & Zebrafish Screening.pdf
(pdf - 75,19 kB)

February 08, 2012
11:50 PM CET